



Media Release

Zurich – 14 August 2008

Nobel Biocare acquires Medicim – the leading developer of innovative medical imaging solutions for treatment planning and guided surgery

Nobel Biocare (NOBN) today announced that it acquired a 100% stake in the Belgian medical solutions company Medicim. Medicim develops innovative CBCT-(cone beam computer tomography) based medical imaging technologies and software for diagnosis therapy, treatment planning and guided surgery solutions.

The acquisition of Medicim will further strengthen Nobel Biocare's leading position in guided surgery and contribute to further develop and integrate the leading guided surgery software NobelGuide with Procera CAD/CAM system for the design and production of individualized products such as crown and bridges.

Nobel Biocare believes that dentistry will increasingly deploy digital tools and replace material flows with digital flows, such as CAD/CAM for the benefit of reduced chair time, lower treatment costs and increased quality. Nobel Biocare strategy is to continuously integrate all systems into a user-friendly and effective application.

Nobel Biocare will combine its own operations with Medicim's, forming a highly specialized business unit for digital dentistry. The new business unit will accelerate the development of next generation software. Nobel Biocare will also take over all of Medicim's patents and its entire innovation pipeline, including Maxilim, a unique treatment-planning software for maxillofacial surgery.

Medicim was founded in 2002 as a spin-off from the University of Leuven (K.U.Leuven) in Belgium and is the inventor of the NobelGuide software.

Nobel Biocare, as the first mover in dental CAD/CAM with the largest installed base in the industry, introduced NobelGuide in 2005. The system is the most widely used guided surgery software with an installed base of more than 5'000 customers.

Domenico Scala, CEO of Nobel Biocare said: "Medicim's capabilities in medical imaging solutions offer us an ideal opportunity to further realize our strategy of being the leading company in integrated digital dental solutions. Medicim's promising platform and pipeline of future treatment planning and guided surgery solutions ideally complement our own initiatives in this field. Combining the strengths of Nobel Biocare and Medicim will create significant value and result in benefits for both dental professionals and their patients."



For further information, please contact:

Media:

Nicolas Weidmann, Vice President Communications
Tel: +41 43 211 42 80, +41 79 372 29 81
E-mail: nicolas.weidmann@nobelbiocare.com

Investor Relations:

Süha Demokan, Head of Investor Relations
Tel: +41 43 211 42 30, +41 79 430 81 46
E-mail: suha.demokan@nobelbiocare.com

Nobel Biocare is a medical devices group and the world leader in innovative esthetic dental solutions with its brands NobelActive™, Brånemark System®, NobelReplace™, NobelSpeedy™, NobelPerfect®, NobelDirect®, Replace Select (dental implants), Procera® (individualized dental prosthetics), NobelGuide™ (complete patient rehabilitation program) and NobelSmile™ (patient education and awareness program). Nobel Biocare is a full solution provider for restorative esthetic dentistry, offering a wide range of innovative Crown & Bridge & Implant products, as well as training and education, patient information and clinically documented treatment concepts. Nobel Biocare has over 2,400 employees and recorded revenues of EUR 665.9 million in 2007. The Company is domiciled and headquartered in Zurich, Switzerland. Production takes place at six production sites located in Sweden, the US, Japan, and Israel. Nobel Biocare has 37 direct sales organizations. The shares of the parent company Nobel Biocare Holding AG are listed on the SWX Swiss Exchange.

www.nobelbiocare.com